
Photo: Depositphotos
Apr 19, 2025, 06:30
David Heredia: Not all Lung adenocarcinomas respond the same
David Heredia, Thoracic oncologist at Punta Médica Hospital, posted on X:
“Not all Lung adenocarcinomas (LUAD) respond the same.
Mucinous LUAD = 10% of cases, often KRAS+, TTF1–, PD-L1 low
Worse outcomes across therapies:
- ICI ORR: 8.4% vs 25.9%
- IO+chemo OS: 11.4 vs 19.6 mo
- KRASG12C OS: 6.8 vs 10.8 mo
Histology matters.”
“Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.”
Authors: A. Di Federico et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 13:43
Apr 19, 2025, 13:05